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Current influenza vaccines are effective but imperfect, failing to cover against emerging 
strains of virus and requiring seasonal administration to protect against new strains. A 
key step to improving influenza vaccines is to improve our understanding of vaccine-in-
duced protection. While it is clear that antibodies play a protective role, vaccine-induced 
CD8+ T cells can improve protection. To further explore the role of CD8+ T cells, we used 
a DNA vaccine that encodes antigen dimerized to an immune cell targeting module. 
Immunizing CB6F1 mice with the DNA vaccine in a heterologous prime-boost regime 
with the seasonal protein vaccine improved the resolution of influenza disease compared 
with protein alone. This improved disease resolution was dependent on CD8+ T cells. 
However, DNA vaccine regimes that induced CD8+ T cells alone were not protective and 
did not boost the protection provided by protein. The MHC-targeting module used was 
an anti-I-Ed single chain antibody specific to the BALB/c strain of mice. To test the role 
of MHC targeting, we compared the response between BALB/c, C57BL/6 mice, and 
an F1 cross of the two strains (CB6F1). BALB/c mice were protected, C57BL/6 were 
not, and the F1 had an intermediate phenotype; showing that the targeting of antigen is 
important in the response. Based on these findings, and in agreement with other studies 
using different vaccines, we conclude that, in addition to antibody, inducing a protective 
CD8 response is important in future influenza vaccines.
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inTrODUcTiOn
The annual burden of influenza is significant, with the WHO estimating one billion cases of infec-
tion a year. Of these, an estimate from 2008 suggests that about 90 million cases are in children 
under 5 years of age (1). This huge burden of disease is in spite of there being seasonal vaccines 
for influenza: these vaccines are not available for the global population and, due to the changing 
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nature of circulating influenza strains, are often not completely 
effective. Ideally, new vaccines with broader cross protection 
would be developed, which address the problem of antigenic 
drift and the narrow window in which a seasonal vaccine is 
effective.
For the current generation of strain-specific protein vac-
cines, antibody is a valuable correlate of protection. Currently 
vaccines are licensed based on a hemagglutination inhibition 
(HAI) titer of 1:40, a surrogate assay for neutralizing antibody. 
However, the HAI assay has limitations, even for assessing 
antibody: it only measures anti-hemagglutinin responses and 
does not recognize all hemagglutinin-specific antibodies, 
for example, it does not detect antibodies that bind the more 
conserved stem region. Therefore, for the next generation of 
influenza vaccines, particularly for cross-reactive vaccines, bet-
ter understanding about the relative contributions of different 
arms of the adaptive immune system in protection is required 
(2). For example, HAI titer fails to take into account the role 
of T cells in the vaccine response to influenza, which may also 
contribute to cross protection (3).
While both CD4+ and CD8+ T cells can contribute to protec-
tion against influenza, CD8+ T cells are particularly beneficial 
when they recognize conserved epitopes across multiple influ-
enza strains (4). The direct evidence for the role of influenza 
disease reduction by CD8+ T cells is mostly derived from animal 
studies, but a recent study correlated influenza-specific CD8+ T 
cells with protection against symptomatic pandemic influenza 
(5). Based on their protective role, CD8+ T cells are an attractive 
target in vaccine development. But, it is of note that CD8+ T 
cells only function after cellular infection has occurred, acting to 
limit rather than prevent infection. Understanding the protec-
tion provided by vaccine-induced CD8+ T cells in the context of 
virus-specific antibody is important in designing new influenza 
vaccines.
One approach to induce different types of adaptive immune 
response is to direct antigen to specific antigen-presenting cells 
(6). This can be achieved using dimeric vaccines with targeting 
modules (either a scFv derived from an antibody or chemokine) 
coupled by a dimerization unit to the antigen (7). Changing the 
module allows the targeting of different antigen-presenting cells, 
leading to different types of immune responses and enabling 
the comparison of the relative contribution of different adaptive 
immune effectors. In previous studies in mice, an MHC-targeting 
module has been shown to induce a dominant IgG1 antibody 
response with some T cell induction (8), while an XCL1 chemokine 
module led to a more skewed CD8+ T cell response (9).
In the current study, we investigated the relative contribution 
of influenza-specific CD8+ T cells induced by a DNA vaccine 
in a heterologous prime-boost regime with a protein vaccine. 
The protein vaccine induced a strong antibody response but 
relatively few CD8 cells. Induction of CD8+ T cells by the dimeric 
vaccine improved the resolution of disease, and when CD8 cells 
were depleted, the enhanced resolution was no longer observed. 
However, CD8 cells alone were insufficient to protect against 
infection. Based on this, we conclude that vaccine-induced CD8 
responses are beneficial but are supplementary to antibody.
MaTerials anD MeThODs
Dna Vaccine constructs
The generation of the DNA vaccine constructs containing the 
targeting unit, the dimerization unit consisting of h1 + h4 + CH3 
domains derived from human IgG3, and antigen has been 
previously described (9, 10). The constructs either expressed 
amino acids 18–541, the extracellular domain, and part of the 
transmembrane domain, of influenza A/California/07/2009 
(H1N1) hemagglutinin or the conserved IYSTVASSL epitope 
of H1 (533–541) as the antigen payload, and anti-I-Ed MHC 
class II single chain variable fragment (scFv) from the 14-4-4S 
monoclonal antibody that binds the conserved E alpha chain, or 
murine XCL1 as the targeting unit. All sequences were synthe-
sized by Eurofins MWG (Germany) or GenScript (USA). The 
synthesized inserts were subcloned into the expression vector 
pUMVC4a on NotI and BglII, all including either an Ig VH signal 
peptide or the murine XCL-1 signal peptide to ensure secretion. 
The αMHCII:HA (Cal/07) construct has been described previ-
ously (8).
Mouse immunization and infection
Six- to eight-week-old female CB6F1, BALB/c, or C57BL/6 
mice were obtained from Harlan UK Ltd. (Bradford, UK) and 
kept in specific pathogen-free conditions in accordance with 
the UK’s Home Office guidelines, and all work was approved 
by the Animal Welfare and Ethical Review Board (AWERB) 
at Imperial College London. Studies followed the ARRIVE 
guidelines. Animals were immunized in a prime (d0)-boost 
(d21)-challenge (d42) regime and culled on day 7 of challenge 
(d49 relative to prime). For protein immunization, mice were 
immunized intramuscularly (i.m.) with 0.1 μg purified surface 
antigens from influenza strain H1N1 A/California/7/2009 
(GSK Vaccines, Siena, Italy) in 50  μl. For DNA vaccination, 
mice were injected i.m. into the anterior tibialis with 5 μg plas-
mid in 50 μl of sterile PBS followed by electroporation (EP). 
Two lots of 5 pulses of 150 V with switched polarity between 
pulses were delivered using a CUY21 EDIT system (BEX, 
Japan). For infections, mice were anesthetized using isoflurane 
and infected intranasally (i.n.) with 5 × 104 PFU of influenza 
A H1N1 (strain A/England/195/2009). Where used, CD8+ 
T cells were depleted using two intraperitoneal injections of 
0.25 mg anti-murine CD8 antibody clone YTS156, and CD4+ 
T cells were depleted with 0.125 mg each of YTA3 and YTS191 
(a kind gift of S. Cobbold, Oxford University) on day −1 and 
+1 of infection (11).
influenza
H1N1 influenza (strain A/England/195/2009), isolated by Public 
Health England in the UK, April 2009 (12), was grown in Madin–
Darby Canine Kidney (MDCK) cells, in serum-free DMEM sup-
plemented with 1 μg/ml trypsin. The virus was harvested 3 days 
after inoculation and stored at −80°C. Viral titer was determined 
by plaque assay as previously described (13).
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semiquantitative antigen-specific elisa
Antibodies specific to influenza H1N1 were measured using 
a standardized ELISA (14). IgG responses were measured in 
sera and IgA responses in bronchoalveolar lavage. MaxiSorp 
96-well plates (Nunc) were coated with 1 μg/ml H1N1 surface 
proteins or a combination of anti-murine lambda and kappa 
light chain-specific antibodies (AbDSerotec, Oxford, UK) and 
incubated overnight at 4°C. Plates were blocked with 1% BSA 
in PBS. Bound IgG was detected using HRP-conjugated goat 
anti-mouse IgG (AbD Serotec). Bound IgA was detected using 
a biotinylated anti-IgA and a streptavidin-HRP. A dilution 
series of recombinant murine IgG or IgA was used as a standard 
to quantify specific antibodies. TMB with H2SO4 as stop solu-
tion was used to detect the response and optical densities read 
at 450 nm.
Tissue and cell recovery and isolation
Mice were culled using 100  μl intraperitoneal pentobarbitone 
(20 mg dose, Pentoject, Animalcare Ltd., UK) and tissues collected 
as previously described (15). Blood was collected from carotid 
vessels and sera isolated after clotting by centrifugation. Lungs 
were removed and homogenized by passage through 100 μm cell 
strainers, then centrifuged at 200 × g for 5 min. Supernatants were 
removed, and the cell pellet treated with red blood cell lysis buffer 
(ACK; 0.15M ammonium chloride, 1M potassium hydrogen 
carbonate, and 0.01 mM EDTA, pH 7.2) before centrifugation at 
200 × g for 5 min. The remaining cells were resuspended in RPMI 
1640 medium with 10% fetal calf serum and viable cell numbers 
determined by trypan blue exclusion.
influenza Viral load
Viral load in  vivo was assessed by Trizol extraction of RNA 
from frozen lung tissue disrupted in a TissueLyzer (Qiagen, 
Manchester, UK). RNA was converted into cDNA, and quan-
titative RT-PCR was carried out using bulk viral RNA, for the 
influenza M gene and mRNA using 0.1  μM forward primer 
(5′-AAGACAAGACCAATYCTGTCACCTCT-3′), 0.1  μM 
reverse primer (5′-TCTACGYTGCAGTCCYCGCT-3′), and 
0.2  μM probe (5′-FAM-TYACGCTCACCGTGCCCAGTG-
TAMRA-3′) on a Stratagene Mx3005p (Agilent technologies, 
Santa Clara, CA, USA). M-specific RNA copy number was 
determined using an influenza M gene standard plasmid.
Flow cytometry
Live cells were suspended in Fc block (Anti-CD16/32, BD) in 
PBS-1% BSA and stained with surface antibodies: influenza A H1 
HA533–541 IYSTVASSL Pentamer R-PE (Proimmune, Oxford, UK), 
CD3-FITC (BD, Oxford UK), CD4-APC (BD), and CD8-APC 
Alexa75 (Invitrogen, Paisley, UK). Analysis was performed on an 
LSRFortessa flow cytometer (BD). FMO controls were used for 
surface stains.
statistical analysis
Calculations as described in figure legends were performed using 
Prism 6 (GraphPad Software Inc., La Jolla, CA, USA).
resUlTs
heterologous Prime-Boost regimes Using 
Dimeric Dna Vaccines induce Both 
antibody and cD8+ T cell responses and 
improve resolution of Disease
Vaccine-induced, antibody-mediated protection against influ-
enza is well characterized, but CD8+ T cells are also important. 
DNA vaccines allow the induction of strong cellular responses 
(16), and the use of different targeting modules allows us to 
compare the relative contributions of different effectors (17). We 
compared the response to immunization using a DNA vaccine 
encoding dimeric APC-targeted antigen alone or in combina-
tion with protein antigens. The DNA vaccine construct for these 
studies encoded the HA gene from influenza Eng/195 (H1N1) 
dimerized to an anti-I-Ed MHC class II scFv with a dimerization 
unit consisting of h1 + h4 + CH3 domains from human IgG3. 
CB6F1 mice were used for these studies, and they are the F1 
cross of BALB/c (I-Ed) and C57BL/6 (I-Eb) strains. Mice were 
immunized once with 5 μg DNA encoding the dimeric vaccine 
construct (αMHCII:HA) i.m. with EP, with or without a boost (on 
day 21), using a sub-protective dose of H1N1 proteins (0.1 μg) 
from CAL/09. Three weeks after the boost immunization (on day 
42), mice were challenged i.n. with H1N1 influenza (strain A/
England/195/2009) and culled 7 days later (day 49).
Blood was collected prior to infection to determine anti-
influenza antibodies. αMHCII:HA primed-protein boosted 
animals had significantly more antibody than protein alone or 
αMHCII:HA alone (p <  0.05, Figure  1A). All immunizations 
gave some reduction of weight loss following influenza infection. 
The αMHCII:HA alone group recovered faster on days 6 and 7 
after infection than PBS control mice, and a similar phenotype 
was seen after immunization with protein alone. However, 
prime immunization with DNA and then protein boost led to 
significantly improved recovery from d4 after infection (p < 0.05 
compared to DNA or protein alone on d5 and d6, Figure 1B). 
After infection, antibody responses in the αMHCII:HA-Protein 
group were the same as the PBS-protein group, and levels were 
10-fold higher than before infection (Figure 1C). There was some 
detectable antibody after immunizing with αMHCII:HA alone, 
which was slightly boosted by infection. However, αMHCII:HA 
alone immunized animals had a significant influenza-specific 
CD8+ T cell response in the lungs, as measured by pentamer-
positive cells, greater than the protein alone or naive animals 
(p <  0.05, Figure  1D). These cells were also induced in the 
prime-boost group. These data suggest that while antibody is 
protective against influenza infection, antigen-specific CD8+ T 
cells contribute to recovery in the absence or near absence of 
antibodies.
accelerated resolution in Prime-Boost 
regimes is Provided by cD8+ T cells
Having observed that heterologous prime-boost immunization 
led to faster recovery, and the DNA vaccines induced both an 
influenza-specific CD8 and antibody response, we wished to 
determine the role of the CD8 cells. Mice were immunized 
FigUre 1 | heterologous prime-boost regimes using dimeric Dna vaccines induce both antibody and cD8+ T cell responses and improves 
resolution of disease. Mice were immunized intramuscularly (i.m.), immediately followed by electroporation, with 5 μg DNA encoding an MHCII-targeting:HA 
construct or 0.1 μg H1N1 proteins or DNA and then protein. Animals were infected intranasally (i.n.) with 5 × 104 PFU A/England/195/2009 H1N1 influenza. One day 
before infection, IgG was assessed in sera (a). Weight change was measured after infection (B). H1 Influenza-specific IgG by ELISA (c) and influenza-specific CD8+ 
T cells (D) were measured on day 7 after infection. Lines and points represent mean of n ≥ 4 mice **p < 0.01, ***p < 0.001 between MHCII:HA-Protein and 
MHCII:HA, #p < 0.05 between MHCII:HA and protein alone measured by one way (B,c) or two-way ANOVA (a).
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with αMHCII:HA with a protein boost or protein alone, and 
responses compared between animals treated with CD8 deplet-
ing antibody and control during infection. As seen before, 
αMHCII:HA-Protein immunization induced more antibody 
than protein alone 21  days after the boost immunization 
(Figure 2A). αMHCII:HA-Protein-immunized, CD8+-depleted 
mice lost significantly more weight than the immunized animals 
with intact CD8+ responses (p < 0.05 on day 6 and 7, Figure 2B). 
CD8 depletion had no effect on protein alone immunization. At 
day 7 after infection, αMHCII:HA-Protein-immunized mice 
had no detectable viral load, and CD8 depletion had no effect 
on this (Figure  2C). CD8 depletion also had no effect on the 
antibody response (Figure 2D) or CD4+ T cell number in the 
lungs (Figure 2E) but led to a significant reduction in both total 
(Figure  2F) and influenza-specific CD8+ T cells (Figure  2G). 
From this, we conclude that the improved recovery seen after 
αMHCII:HA priming before protein vaccination is partially 
mediated by CD8+ cells.
cD8+ cells in isolation are not sufficient 
for Protection from influenza infection
Since we observed that CD8 cells contribute to the accelerated 
resolution of disease in the prime-boost immunization, we wished 
to determine whether vaccines inducing influenza-specific CD8 
alone could also improve disease resolution. A pilot study was 
performed to determine the immune response vaccine constructs 
using different targeting unit/antigen combinations, in order 
to select the ones that gave the greatest CD8+ T cell responses. 
Mice were immunized with constructs encoding either anti-I-
Ed scFv or the XCL1-targeting module with either the full HA 
surface domain (of Cal/07) or the Kd immunodominant epitope 
alone in H1 hemagglutinin (HA533–541 IYSTVASSL). The groups 
immunized with constructs encoding the epitope alone were 
not protected against influenza infection (Figures  3A,B). The 
more complete HA constructs offered modest protection with 
αMHCII:HA-immunized animals recovering slightly faster than 
the naive animals, and the XCL1:HA-immunized animals gaining 
FigUre 2 | cD8+ T cells required for accelerated resolution of Dna prime-boost regimes. CB6F1 mice were immunized i.m. with 5 μg DNA encoding 
MHCII:HA, then 0.1 μg H1N1 proteins, or protein alone. 21 days later, mice were infected intranasally with H1N1 influenza. CD8+ T cells were depleted by antibody 
(YTS156) on day −1 and +1 of infection. One day before infection, IgG was assessed in sera (a). Weight change was measured after infection (B). M gene copy 
number (c), H1 Influenza-specific antibody by ELISA (D), CD4+ (e), and CD8+ (F) and influenza-specific CD8+ T cells (g) were measured on day 7 after infection. 
Lines and points represent mean of n = 5 mice *p < 0.05, **p < 0.01 between MHCII:HA-protein and MHCII:HA-protein αCD8 measured by one-way ANOVA.
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weight on d7 post infection. There were striking differences in the 
antibody responses: only animals immunized with a construct 
expressing the whole HA had detectable antibody responses, 
and the response to the MHCII-targeting construct was greater 
than the XCL1 (Figure 3C). While the antibody responses were 
poor to these constructs, there was substantial recruitment of 
influenza-specific CD8+ T cells. All immunized groups had 
influenza-specific T cells in the lungs, but there were greater 
responses in the epitope-immunized animals (Figure 3D). From 
this pilot study, we conclude that the epitope-only vaccines induce 
a stronger CD8 response.
To assess the relative contributions of CD8+ cells versus 
antibody, we took advantage of the differential responses to the 
αMHCII:HA or αMHCII:Epitope constructs, with either a DNA 
or protein boost, prior to infection with influenza. Prime-boost 
regimes with protein or αMHCII:HA (Eng/195) led to significant 
protection against infection, with little difference between the 
homologous or heterologous prime-boost regimes in weight loss 
(Figure  4A). Protein-containing regimes (Protein–Protein or 
αMHCII:HA-Protein) had slightly less detectable viral RNA in 
the lungs than the αMHCII:HA homologous regime (Figure 4B). 
The groups receiving a protein vaccination had more antibody 
than the other groups (Figure  4C), though it was surprising 
that there was no boost in antibody response after the second 
protein immunization. The regimes using the αMHCII:Epitope 
induced the greatest level of CD8+ cells in the lungs after infec-
tion (p < 0.05, Figure 4D), but the αMHCII:Epitope-immunized 
animals were not protected against infection, losing a similar 
amount of weight as naive animals and having an equivalent viral 
load. Priming with αMHCII:Epitope followed by protein did lead 
to significantly more CD8+ T cells than Protein–Protein but had 
little effect on protection. As seen before, the protein-only immu-
nization regime did not induce any influenza-specific CD8+ T 
cells. These data suggest influenza-specific CD8+T cells targeting 
the IYSTVASSL epitope of H1 are not sufficient to protect against 
infection.
Mouse strain Key Determinant of 
Protection for Mhcii Targeting constructs
In previous studies using similar DNA vaccine constructs in 
BALB/c mice, complete protection against Cal/07 infection was 
observed after a single DNA vaccination (8). Possible sources of 
differences include the amount of DNA delivered (25 μg in pub-
lished, 5 μg in current), the route of delivery (i.d. in published, 
i.m. in current), viruses used for challenge (Cal/07 in published, 
Eng/195 in current: the HA genes from Cal/07 and Eng/195 are 
FigUre 3 | Pilot study comparing cD8 response to different dimeric vaccine constructs. CB6F1 mice were primed i.m. with 5 μg DNA constructs targeting 
either MHC II or the XCR1 chemokine receptor, conjugated to the full HA peptide or the immunodominant epitope alone (epi). Animals were infected i.n. with 
Eng/195 H1N1 influenza. Weight change was measured after infection (a), with day 7 weight alone shown for clarity (B). H1 Influenza-specific antibody by ELISA 
(c) and influenza-specific CD8 T cells (D) were measured on day 7 after infection. Lines and points represent mean of n ≥ 3 mice.
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99% identical, with 4 amino acid changes), the mouse strains 
used (BALB/c in published, CB6F1 in current), or the antigens 
inserted into the MHCII-targeted construct. To ensure that 
there was no difference between constructs used in the current 
study and the published constructs, we compared immunization 
with the construct used in the previous study (8) and a construct 
expressing the HA from Eng/195. CB6F1 mice were immunized 
with 5 μg of each construct with EP, and 28 days later, they were 
infected i.n. with 5 × 104 PFU of ENG195. Weight was meas-
ured daily after infection, and there was no difference between 
mice immunized with the two vaccine constructs; immunized 
mice recovered faster than naive mice on day 7 after infection 
(Figure  5A). Significantly, more viral RNA was detected in 
the lungs of previously naive animals than in immunized ani-
mals, and there was no difference in viral load between mice 
immunized with either construct (Figure 5B). Both constructs 
induced an immune response, as there was detectable specific 
IgG in the sera at d7 (Figure 5C) and flu-specific CD8+ T cells in 
the lung (Figure 5D) in immunized but not naive animals. From 
this, we conclude that the incomplete protection observed in the 
initial studies was not due to the construct, the antigen targeted, 
or the challenge virus, suggesting that mouse strain may be 
important, though the dose and route may also contribute to 
differences seen.
compatibility of host strain and Vaccine 
construct Mhc-Targeting Unit is critical 
in level of Protection
The targeting unit of the MHC vaccine construct is based on an 
scFv, derived from the 14-4-4S monoclonal antibody that binds 
the conserved E alpha chain of the I-Ed MHCII molecule, which 
is expressed in mouse strains that are H-2d. We have previously 
observed that mouse strain is critical in the recall immune 
response to respiratory viral infection (18). Previously published 
studies with similar MHC-targeting vaccine constructs used 
BALB/c mice (H-2d), and the current studies used CB6F1 mice, 
FigUre 4 | The combination of antigens used in the prime-boost regime is critical in determining outcome. CB6F1 mice were primed i.m. with 5 μg DNA 
constructs encoding MHCII:HA, or MHCII:Epitope, or 0.1 μg HA1 protein prior either heterologous or homologous boost. Twenty-one days after boost, animals were 
infected i.n. with Eng/195 H1N1 influenza. Weight change was measured after infection (a). M gene copy number (B), H1 influenza-specific antibody by ELISA (c), 
and influenza-specific CD8+ T cells (D) were measured on day 7 after infection. Lines and points represent mean of n = 5 mice *p < 0.05, **p < 0.01 measured by 
one-way ANOVA.
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which are mixed H-2d and H-2b. To test whether mouse strain 
has an effect on the immune response to the vaccine, we immu-
nized BALB/c (H-2d), C57BL/6 (H-2b), and CB6F1 (mixed H-2d 
and H-2b) with the αMHCII:HA construct. These animals were 
then challenged with influenza. Naive animals started losing 
weight on day 2 after infection, and this weight loss continued 
to day 7, at which point the animals were culled (Figure 6A). 
There was no significant difference in the magnitude or the 
profile of the weight loss between the naive animals regardless 
of strain, indicating that baseline susceptibility to influenza was 
similar. However, there was a striking difference in protection 
based on MHC genotype. BALB/c were more protected than 
F1 mice, which were more protected than the C57BL/6 mice, 
directly reflecting the amount of I-Ed MHC (Figures 6B–D) and 
FigUre 5 | incomplete protection with both cal07- and eng195-encoding constructs in cB6F1 mice. Mice were immunized intramuscularly with 5 μg DNA 
encoding different antigen-targeting module constructs with electroporation, prior to infection intranasally with 5 × 104 PFU A/England/195/2009 H1N1 influenza. 
Weight change was measured after infection (a). M gene copy number (B), H1 Influenza-specific antibody by ELISA (c), and influenza-specific CD8+ T cells (D) 
were measured on day 7 after infection. n = 5 animals per group, **p < 0.01 and ***p < 0.001 using ANOVA and posttest.
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reflecting the previously published study (8). Likewise, there was 
only a reduction in viral load in the BALB/c and F1-immunized 
mice (Figure  6E). There was detectable influenza-specific 
antibody (Figure 6F) and CD8+ T cells (Figure 6G) in both the 
BALB/c and CB6F1 mice, and there was no difference between 
the two strains, suggesting that there are other components that 
contribute to protection against infection. The BALB/c mice had 
a higher proportion of CD4+ T cells in the lungs, which may 
have contributed to protection (Figure  6H), but in a separate 
study when treated with CD4-depleting antibody during chal-
lenge, there was no effect on resolution of disease after depletion 
(Figure 6I).
In the CB6F1 mice, the regimes that induced CD8+ T cells alone 
did not protect against infection. Since we observed a difference 
between BALB/c and CB6F1 mice in protection following immu-
nization with the αMHCII:HA construct, we wished to determine 
whether there was a difference in the protective capacity of the 
CD8+ T cells induced in H-2b mice. BALB/c were immunized 
twice with the MHCII-epitope construct prior to infection with 
influenza. Mice were not protected against infection (Figure 6J) 
despite inducing an extremely high influenza-specific CD8 
response (Figure  6K). As with the CB6F1 mice, no antibody 
response was seen after immunization with this construct (data 
not shown). These studies clearly demonstrate the effect of the 
targeting module on the response.
DiscUssiOn
In this study we observed that a DNA vaccine encoding a dimeric 
construct that targets hemagglutinin to antigen-presenting cells 
can induce an influenza-specific CD8+ T cell response, which in 
the context of antibody can lead to more rapid recovery from infec-
tion. CD8 cell depletion removed the extra protection provided 
by the DNA vaccination. It should be noted that the MHCII:HA 
DNA-prime protein-boost regime induced more antibody than 
protein alone prior to infection, which will contribute to the 
additional protection seen; but the depletion studies suggest 
that the additional protection provided by elevated antibody was 
secondary to that provided by CD8. From this, we conclude that 
CD8 contribute to protection against influenza infection but are 
insufficient when acting alone.
The H1 hemagglutinin epitope (IYSTVASSL) only DNA con-
structs were insufficient to protect against influenza infection in 
spite of inducing robust CD8 responses in the lung during infec-
tion. There were a number of possible reasons why immunization 
that only induces a CD8 response fails to protect against influenza 
challenge including immunopathology, the infectious dose used, 
the DNA vaccine dose used, targeting a poorly protective epitope 
or immunizing the wrong tissue. Excess CD8+ T cells can be 
associated with disease, both for influenza (19) and respiratory 
syncytial virus (RSV) infection (20). But, there was little evidence 
FigUre 6 | strain compatibility with Mhc-targeting module affects protection against challenge. Mice were immunized intramuscularly with 5 μg DNA 
encoding an I-Ed MHCII targeting-HA construct with electroporation, prior to infection intranasally with 5 × 104 PFU A/England/195/2009 H1N1 influenza. Weight 
change was measured after infection (a). The same data are presented by strain for clarity: BALB/c (B), CB6F1 (c), and C57BL/6 (D). M gene copy number (e), H1 
Influenza-specific antibody by ELISA (F), influenza-specific CD8+ T cells (g), and % CD4+ T cells (h) were measured on day 7 after infection. Weight loss of 
MHCII:HA immunized BALB/c mice treated with CD4 depleting antibody during infection (i). BALB/c mice were immunized two times intramuscularly with 5 μg DNA 
encoding an I-Ed MHCII targeting-epitope construct with electroporation prior to infection. Weight change was measured after infection (J). On day 7 after infection, 
percentages of influenza-specific CD8+ T cells were quantified (K). n = 5 animals per group.
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for CD8 cells causing enhanced immunopathology in the current 
study – for example, the MHCII:Epitope construct induced little 
antibody and high levels of CD8 cells, but the disease profile 
was the same as naive mice. A different epitope might be more 
protective; the current study evaluated a CD8 epitope in hema-
glutinin, and CD8 responses against the NP protein of influenza 
have been explored for vaccine candidates (21). Though in other 
studies, the IYSTVASSL (HA533) epitope has been used as a 
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heterologous boost vaccine, expressed by Listeria (22), leading to 
heterosubtypic immunity, differences in route, dose, regime, and 
vector of delivery could all contribute to the differences seen. It 
is possible that, in the absence of antibody, CD8 cells are being 
swamped by virus: with a smaller infectious challenge dose, CD8 
cells may have provided more protection (23), but the viral dose 
used has been carefully titrated to give a clear disease phenotype. 
It was of note that the αMHCII:HA and other DNA vaccines used 
in other studies (24, 25) were protective against the same dose of 
the same virus; notably, all of these regimes induced antibody and 
CD8 T cells, indicating that both are required.
Another possibility is that the CD8 cells induced by vaccina-
tion were in the wrong tissue. Systemic vaccination is most likely 
to lead to systemic T cell memory, resident in the spleen, whereas 
CD8 in the lung are required to clear the infection. The time 
taken to recruit cells in response to infection from the systemic 
to the local compartment may account for the failure to clear the 
infection. Tissue-resident memory CD8 cells have been shown to 
be critical in protection, and vaccine regimes that induce them 
have a significantly improved outcome compared with systemic 
vaccination (26). One approach might be to use live viral vac-
cines - the use of the live attenuated influenza vaccine led to the 
induction of influenza-specific CD8 T cells in the lungs (27) - and 
we have recently shown that heterologous prime-boost strategies 
including viral vectors can alter the immune outcome (28).
One of the striking observations was the effect of mouse 
MHC genotype on the response to the MHC-targeting vaccine 
constructs. This shows that the targeting component of the 
dimeric vaccine is critical in the response it induces. But the 
homozygous I-Ed strain (BALB/c) was most protected against 
infection, in spite of having broadly similar antibody and CD8+ 
T cell responses to the heterozygous CB6F1 mice. C57BL/6 mice 
were not protected due to their lack of I-Ed. One possibility is 
that hemagglutinin-specific CD4 cells were also induced by 
the vaccine and there more of these in the BALB/c mice than 
the CB6F1. There are two well-characterized MHCII epitopes 
in H1-derived hemagglutinin SVSSFERFEIFPK (H2-IEd posi-
tions 124–136) and HNTNGVTAACSHE (H2-IAd positions 
139–151), and αMHCII:HA can induce responses against these 
(8). The role of CD4 cells in protection against influenza is less 
well characterized than CD8, but recent studies have shown a 
correlation between CD4 T cell responses and protection in 
a human influenza challenge study (29). Whether these cells 
play a role and what role they play – either as helpers (30) or 
as cytotoxic T cells (31) – is not clear, though the depletion of 
CD4 during challenge had no effect on disease outcome, sug-
gesting that they are not acting as cytotoxic effectors but may be 
important in priming the response.
The best protection was observed when both CD8 and antibody 
were induced. This reflects other studies using the dimeric vac-
cine constructs expressing hemagglutinin (8, 9, 32) all of which 
induced both antibody and CD8 T cells. We believe that CD8 play 
a critical role in the later stages of the infection leading to viral 
clearance and recovery from influenza infection, providing an 
adjunct to antibody-mediated protection. Studies in human RSV 
showed that the probability of protection from antibody follows 
a sigmoidal distribution suggesting a role for other factors (33). 
We propose a model where antibody prevents the initial coloniza-
tion, but if antibody is evaded by the virus, then CD8 cells enable 
more rapid clearance. In this context, vaccines that can induce 
local CD8 responses may be of value, particularly if they target 
conserved epitopes.
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